Effects of IGF-I on renal function in end-stage chronic renal failure

Steven B. Miller, Michael Moulton, Michael O'Shea, Marc R. Hammerman

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

To determine whether insulin-like growth factor I (IGF-I) affects kidney function in patients with end-stage chronic renal failure, we administered recombinant human IGF-I (rhIGF-I) (100 μg/kg body wt subcutaneously twice daily) to nine individuals with baseline inulin clearances below 21 ml/min/1.73 m2. Four patients were treated for four days (short-term treatment) and five for periods between 13 and 27 days (long-term treatment). Administration of rhIGF-I increased inulin clearance, p-aminohippurate (PAH) clearance and the percent tubular reabsorption of filtered phosphate, and decreased plasma creatinine, blood urea nitrogen (BUN) and plasma phosphate during short-term administration. Kidney volume was unchanged in patients receiving the growth factor. rhIGF-I did not cause weight gain, proteinuria or hypoglycemia. Inulin clearance was not increased significantly above baseline after 13 or 20 days of IGF-I administration. PAH clearance remained elevated after 13 days, but not after 20 days of IGF-I. Levels of total circulating IGF-I were elevated above basal levels during the entire course of long-term IGF-I administration. In contrast, levels of circulating IGF binding protein 3 (IGFBP3) declined over time. Side effects related to IGF-I forced discontinuation of its use in two of five patients undergoing long-term treatment, and side-effects possibly related to IGF-I prompted discontinuation of its use in two others. We conclude that rhIGF-I can enhance glomerular filtration rate and renal plasma flow when administered short-term to humans with end-stage chronic renal renal failure. Further studies will be required to define its efficacy and usefulness long-term.

Original languageEnglish (US)
Pages (from-to)201-207
Number of pages7
JournalKidney International
Volume46
Issue number1
DOIs
StatePublished - Jul 1994

Fingerprint

Insulin-Like Growth Factor I
Chronic Kidney Failure
Kidney
Inulin
p-Aminohippuric Acid
Phosphates
Renal Plasma Flow
Insulin-Like Growth Factor Binding Protein 3
Blood Urea Nitrogen
Glomerular Filtration Rate
Proteinuria
Hypoglycemia
Weight Gain
Renal Insufficiency
Creatinine
Intercellular Signaling Peptides and Proteins
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Effects of IGF-I on renal function in end-stage chronic renal failure. / Miller, Steven B.; Moulton, Michael; O'Shea, Michael; Hammerman, Marc R.

In: Kidney International, Vol. 46, No. 1, 07.1994, p. 201-207.

Research output: Contribution to journalArticle

Miller, Steven B. ; Moulton, Michael ; O'Shea, Michael ; Hammerman, Marc R. / Effects of IGF-I on renal function in end-stage chronic renal failure. In: Kidney International. 1994 ; Vol. 46, No. 1. pp. 201-207.
@article{3fc61e3dcf4d40e99ec7eddd747cf3e7,
title = "Effects of IGF-I on renal function in end-stage chronic renal failure",
abstract = "To determine whether insulin-like growth factor I (IGF-I) affects kidney function in patients with end-stage chronic renal failure, we administered recombinant human IGF-I (rhIGF-I) (100 μg/kg body wt subcutaneously twice daily) to nine individuals with baseline inulin clearances below 21 ml/min/1.73 m2. Four patients were treated for four days (short-term treatment) and five for periods between 13 and 27 days (long-term treatment). Administration of rhIGF-I increased inulin clearance, p-aminohippurate (PAH) clearance and the percent tubular reabsorption of filtered phosphate, and decreased plasma creatinine, blood urea nitrogen (BUN) and plasma phosphate during short-term administration. Kidney volume was unchanged in patients receiving the growth factor. rhIGF-I did not cause weight gain, proteinuria or hypoglycemia. Inulin clearance was not increased significantly above baseline after 13 or 20 days of IGF-I administration. PAH clearance remained elevated after 13 days, but not after 20 days of IGF-I. Levels of total circulating IGF-I were elevated above basal levels during the entire course of long-term IGF-I administration. In contrast, levels of circulating IGF binding protein 3 (IGFBP3) declined over time. Side effects related to IGF-I forced discontinuation of its use in two of five patients undergoing long-term treatment, and side-effects possibly related to IGF-I prompted discontinuation of its use in two others. We conclude that rhIGF-I can enhance glomerular filtration rate and renal plasma flow when administered short-term to humans with end-stage chronic renal renal failure. Further studies will be required to define its efficacy and usefulness long-term.",
author = "Miller, {Steven B.} and Michael Moulton and Michael O'Shea and Hammerman, {Marc R.}",
year = "1994",
month = "7",
doi = "10.1038/ki.1994.260",
language = "English (US)",
volume = "46",
pages = "201--207",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effects of IGF-I on renal function in end-stage chronic renal failure

AU - Miller, Steven B.

AU - Moulton, Michael

AU - O'Shea, Michael

AU - Hammerman, Marc R.

PY - 1994/7

Y1 - 1994/7

N2 - To determine whether insulin-like growth factor I (IGF-I) affects kidney function in patients with end-stage chronic renal failure, we administered recombinant human IGF-I (rhIGF-I) (100 μg/kg body wt subcutaneously twice daily) to nine individuals with baseline inulin clearances below 21 ml/min/1.73 m2. Four patients were treated for four days (short-term treatment) and five for periods between 13 and 27 days (long-term treatment). Administration of rhIGF-I increased inulin clearance, p-aminohippurate (PAH) clearance and the percent tubular reabsorption of filtered phosphate, and decreased plasma creatinine, blood urea nitrogen (BUN) and plasma phosphate during short-term administration. Kidney volume was unchanged in patients receiving the growth factor. rhIGF-I did not cause weight gain, proteinuria or hypoglycemia. Inulin clearance was not increased significantly above baseline after 13 or 20 days of IGF-I administration. PAH clearance remained elevated after 13 days, but not after 20 days of IGF-I. Levels of total circulating IGF-I were elevated above basal levels during the entire course of long-term IGF-I administration. In contrast, levels of circulating IGF binding protein 3 (IGFBP3) declined over time. Side effects related to IGF-I forced discontinuation of its use in two of five patients undergoing long-term treatment, and side-effects possibly related to IGF-I prompted discontinuation of its use in two others. We conclude that rhIGF-I can enhance glomerular filtration rate and renal plasma flow when administered short-term to humans with end-stage chronic renal renal failure. Further studies will be required to define its efficacy and usefulness long-term.

AB - To determine whether insulin-like growth factor I (IGF-I) affects kidney function in patients with end-stage chronic renal failure, we administered recombinant human IGF-I (rhIGF-I) (100 μg/kg body wt subcutaneously twice daily) to nine individuals with baseline inulin clearances below 21 ml/min/1.73 m2. Four patients were treated for four days (short-term treatment) and five for periods between 13 and 27 days (long-term treatment). Administration of rhIGF-I increased inulin clearance, p-aminohippurate (PAH) clearance and the percent tubular reabsorption of filtered phosphate, and decreased plasma creatinine, blood urea nitrogen (BUN) and plasma phosphate during short-term administration. Kidney volume was unchanged in patients receiving the growth factor. rhIGF-I did not cause weight gain, proteinuria or hypoglycemia. Inulin clearance was not increased significantly above baseline after 13 or 20 days of IGF-I administration. PAH clearance remained elevated after 13 days, but not after 20 days of IGF-I. Levels of total circulating IGF-I were elevated above basal levels during the entire course of long-term IGF-I administration. In contrast, levels of circulating IGF binding protein 3 (IGFBP3) declined over time. Side effects related to IGF-I forced discontinuation of its use in two of five patients undergoing long-term treatment, and side-effects possibly related to IGF-I prompted discontinuation of its use in two others. We conclude that rhIGF-I can enhance glomerular filtration rate and renal plasma flow when administered short-term to humans with end-stage chronic renal renal failure. Further studies will be required to define its efficacy and usefulness long-term.

UR - http://www.scopus.com/inward/record.url?scp=0028346458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028346458&partnerID=8YFLogxK

U2 - 10.1038/ki.1994.260

DO - 10.1038/ki.1994.260

M3 - Article

C2 - 7933838

AN - SCOPUS:0028346458

VL - 46

SP - 201

EP - 207

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -